What is HC Wainwright's Estimate for GALT Q2 Earnings?

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings estimates for shares of Galectin Therapeutics in a research report issued to clients and investors on Tuesday, June 17th. HC Wainwright analyst M. Keller expects that the company will post earnings of ($0.16) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $6.00 target price on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics' Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.67) EPS, FY2026 earnings at ($0.65) EPS and FY2027 earnings at ($0.72) EPS.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.05.

Separately, Wall Street Zen raised shares of Galectin Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday.

Galectin Therapeutics Trading Down 26.4%

NASDAQ GALT traded down $0.87 during trading hours on Thursday, reaching $2.42. The company had a trading volume of 4,322,334 shares, compared to its average volume of 406,496. The stock has a 50-day moving average of $1.45 and a 200 day moving average of $1.44. Galectin Therapeutics has a 1-year low of $0.73 and a 1-year high of $3.90. The stock has a market capitalization of $153.16 million, a P/E ratio of -3.36 and a beta of 0.54.

Institutional Trading of Galectin Therapeutics

Several hedge funds have recently made changes to their positions in GALT. Bank of New York Mellon Corp lifted its position in shares of Galectin Therapeutics by 19.0% during the fourth quarter. Bank of New York Mellon Corp now owns 50,826 shares of the company's stock worth $66,000 after purchasing an additional 8,105 shares in the last quarter. PNC Financial Services Group Inc. acquired a new stake in shares of Galectin Therapeutics during the fourth quarter worth about $26,000. Inspire Advisors LLC lifted its position in shares of Galectin Therapeutics by 86.3% during the fourth quarter. Inspire Advisors LLC now owns 21,095 shares of the company's stock worth $27,000 after purchasing an additional 9,772 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of Galectin Therapeutics during the fourth quarter worth about $29,000. Finally, LPL Financial LLC lifted its position in shares of Galectin Therapeutics by 69.6% during the fourth quarter. LPL Financial LLC now owns 138,928 shares of the company's stock worth $179,000 after purchasing an additional 57,020 shares in the last quarter. Institutional investors and hedge funds own 11.68% of the company's stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.